ADCs as Targeted Therapies: Are We There Yet?

Time: 2:30 pm
day: day 1 track 3 pm


• Are ADCs truly delivering on
the promise of broadened
therapeutic window via targeted
delivery of the payload? A
critical review of the approved
molecules suggest modest
improvements in TI.
• In addition to targeting, multiple
mechanisms of actions seem
to be contributing to clinical
efficacy of late stage molecules.
• Pharmacokinetics-based
assessment indicate a possible
mechanism of actions to be
the extended-release of a
permeable payload to the
systemic circulation